コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ons, and urologic procedures to manage gross hematuria).
2 nephrosis requiring nephrostomy due to gross hematuria).
3 me, 68% had renal insufficiency, and 77% had hematuria.
4 s with persistent, asymptomatic, microscopic hematuria.
5 rtion of patients with persistent glomerular hematuria.
6 osis and management of persistent glomerular hematuria.
7 ons typically cause isolated, nonprogressive hematuria.
8 lify the imaging evaluation of patients with hematuria.
9 l subjects and in four of five patients with hematuria.
10 the characteristic presentation of painless hematuria.
11 cluded proteinuria, renal insufficiency, and hematuria.
12 urinary tract infections, renal stones, and hematuria.
13 f AKI, including proteinuria with or without hematuria.
14 isodes of microscopic or gross nonglomerular hematuria.
15 cant association was not observed in case of hematuria.
16 pients who present with gross or microscopic hematuria.
17 ht patients presented with fever and ten had hematuria.
18 nted with nephrotic syndrome and microscopic hematuria.
19 rular damage and more severe proteinuria and hematuria.
20 ation significantly reduced the incidence of hematuria.
21 ted with a significantly lower risk of gross hematuria.
22 sent with nephrotic syndrome and microscopic hematuria.
23 were not previously identified in a GWAS of hematuria.
24 y reported AE being asymptomatic microscopic hematuria.
25 ceeded that of ANCA titers, proteinuria, and hematuria.
26 gic procedure to investigate or manage gross hematuria.
27 hematuria and those with negative or minimal hematuria.
28 ancer detection in the initial evaluation of hematuria.
29 ions for clinicians evaluating patients with hematuria.
30 oscopic hematuria about any history of gross hematuria.
31 ted free light chain ratio, proteinuria, and hematuria.
32 ant proportions and may present with massive hematuria.
33 families, respectively) and benign familial hematuria.
34 ing, or infected stone causing pain or gross hematuria.
35 department due to right-sided flank pain and hematuria.
36 pack-year history of smoking developed gross hematuria.
37 although without significant proteinuria or hematuria.
38 nclude Alport's syndrome and benign familial hematurias.
41 on (UTI), 8; gross hematuria, 5; microscopic hematuria, 2; dysuria without infection, 6; difficulty v
42 loped renal-related complications, including hematuria (24 patients), urinoma (15 patients), urinary
43 opsy-confirmed IgAN with kidney C3 deposits, hematuria, 24-hour proteinuria above 1.5 g/day, and eGFR
44 left abdomen for one month and an episode of hematuria 3 days earlier accompanied by an attack of acu
46 7), bacterial urinary tract infection (3/7), hematuria (3/7), cytomegalovirus infection (3/7), and im
47 turia than patients with minimal or negative hematuria (30.4% and 37.0% versus 10.6% and 15.2%, respe
48 93, P = .04), driven primarily by reports of hematuria: 4.3% (bevacizumab), 0.7% (sham), 0.2% (aflibe
49 were urinary tract infection (UTI), 8; gross hematuria, 5; microscopic hematuria, 2; dysuria without
50 redictors were 15.6% (15 of 96 patients) for hematuria, 6.0% (13 of 216) for lower rib fractures, 7.6
51 ta on 21 patients showed proteinuria (100%), hematuria (75%), kidney insufficiency and nephrotic synd
52 (-66%+/-2%), percentage of participants with hematuria (-75%; 95% confidence intervals, -87 to -59; i
56 adder stones, blockage, false passage, gross hematuria, accidental removal, urine leakage, or urethra
58 nce therapy, serum creatinine and persistent hematuria after induction, a UPCR of 0.05 g/mmol or more
59 ominal hemorrhage and one case each of gross hematuria, allograft pancreatitis, and severe pain requi
61 ith SCI, 13.5% (CI, 3.4% to 21.9%) had gross hematuria and 1.0% (CI, 0.0% to 5.0%) developed bladder
62 Overall, we identified 2.9% of patients with hematuria and 1.0% with proteinuria during a median foll
63 tion therapy, 157/526 (29.8%) had persistent hematuria and 165/481 (34.3%) had UPCR of 0.05 g/mmol or
64 cystoscopy was performed in 13 patients with hematuria and abnormal findings at conventional cystosco
71 opathies invariably present with microscopic hematuria and frequently progress to proteinuria and CKD
72 cycline-treated C57BL/6 x SJL mice developed hematuria and glomerulonephritis on the MR and standard
77 s (questions and answers) on 5 urology CPGs (hematuria and priapism [HP]; staghorn calculi, infertili
78 re age 1 year, have persistent hypertension, hematuria and proteinuria (sometimes in the nephrotic ra
79 antibody (ANCA)-associated vasculitis (AAV), hematuria and proteinuria are biomarkers reflecting kidn
83 The review will discuss the major causes of hematuria and proteinuria in the pediatric population, a
88 ticle describes the clinical epidemiology of hematuria and the current state of practice and science
89 classified patients as those with persistent hematuria and those with negative or minimal hematuria.
91 h sickle cell trait who presented with gross hematuria and was subsequently found to have renal papil
93 d with 86-24 Stm(r) or B2F1 Stm(r) developed hematuria and/or histological damage to glomeruli or thr
94 l pelvis with calculus increases the risk of hematuria and/or hydronephrosis, presenting with colicky
96 on of this in cases of otherwise unexplained hematuria), and human immunodeficiency virus-associated
100 et of hypertension, early and frequent gross hematuria, and among women, three or more pregnancies.
103 body levels, the presence of proteinuria and hematuria, and by histopathologic analysis of kidney tis
106 sent with normal renal function, microscopic hematuria, and minimal or no proteinuria is not well des
109 complexes resulting in kidney inflammation, hematuria, and proteinuria, mice expressing IgA1 only di
111 Therefore, the prevalence of proteinuria, hematuria, and reduced GFR in the Australian adult popul
113 ociates with impaired urinary concentration, hematuria, and renal papillary necrosis, but its prevale
116 uria, the presence of persistent microscopic hematuria, and the rate of eGFR loss, combined with the
121 ian adult population has either proteinuria, hematuria, and/or reduced GFR, indicating the presence o
123 teinuria; age, gender, and hypertension with hematuria; and age, gender, and hypertension with reduce
124 n causes an astonishing breadth of sequelae: hematuria, anemia, dysuria, stunting, uremia, bladder ca
125 ere thrombocytopenia plus head trauma and/or hematuria appeared to be at particularly high risk of IC
126 forms of urolithiasis, acute flank pain and hematuria are the typical symptoms of indinavir urolithi
131 ntrols with prior urinary tract infection or hematuria because urinary symptoms resulting in antibiot
132 Similarly, those who had an episode of gross hematuria before age 30 had a worse renal outcome than t
143 1 month after the last dose (P < 0.005), and hematuria disappeared in all 5 patients with significant
144 or renal disorders involving proteinuria and hematuria due to podocytopathy and/or segmental splittin
145 acility complaining of weight-loss, fatigue, hematuria, dysuria, painful right inguinal ulceration, a
146 CE 6: Clinicians should pursue evaluation of hematuria even if the patient is receiving antiplatelet
148 were influenced primarily by differences in hematuria events, which may be a result of differential
150 9-year-old patient was admitted with massive hematuria following transurethral resection of prostate
151 calculi in his urine after the occurrence of hematuria, following which pain decreased in intensity.
154 five of 56 (9%) participants and were minor (hematuria, four participants; hematospermia, one partici
156 veraged proteinuria >0.75 g/d and persistent hematuria had significantly worse renal survival than th
157 unodepletion before TGN markedly exacerbated hematuria (hemorrhage), inflammation, and injury, wherea
158 merular defects), microscopic urinalysis for hematuria (hemorrhagic cystitis, bladder cancer), ECG (a
160 statin was associated with increased risk of hematuria (HR, 1.08; 95% confidence interval [95% CI], 1
161 ected in 2.4% of cases (95% CI: 1.6%, 3.1%), hematuria in 4.6% (95% CI: 3.8%, 5.4%), and reduced GFR
162 arin") increased serum creatinine levels and hematuria in 5/6-nephrectomized rats but not in controls
163 sits and reduces inflammation, fibrosis, and hematuria in a mouse IgAN model, and therefore may be a
164 lpha3alpha4alpha5(IV) network, progress from hematuria in early childhood to proteinuria, chronic kid
165 or assembly of a defective scaffold, causing hematuria in nearly all cases, proteinuria, and often pr
168 ing in adults with microscopically confirmed hematuria in the absence of some demonstrable benign cau
169 moking history presented with painless gross hematuria in the fall of 2015 and was ultimately diagnos
171 RE ADVICE 1: Clinicians should include gross hematuria in their routine review of systems and specifi
177 mal electrocardiogram findings, proteinuria, hematuria, low hemoglobin level, elevated erythrocyte se
178 ted liver transaminases (LR range, 2.5-5.2), hematuria (LR range, 3.7-4.1), anemia (LR range, 2.2-3.3
180 he high NPV of CT urography in patients with hematuria may obviate cystoscopy in selected patients.
181 more prominent hypertension and microscopic hematuria may provide clues to the presence of HCV-GD, r
182 cations, including urinary tract infections, hematuria, metabolic acidosis, dehydration, and reflux p
183 lated complications defined as pain, visible hematuria, migration, fragmentation, and urinary tract i
184 of hypothetical predictors of missed injury: hematuria (n = 96) or fracture of the sixth through 12th
187 maging, prior suspected stone episode, gross hematuria, nonobstructing (asymptomatic) stone on imagin
190 y fever, myalgias, pruritus, and proteinuria/hematuria, occurred in 83% vs 50% of those receiving tri
191 Urine protein-creatinine ratio (UPCR) and hematuria of spot urine samples collected at the end of
192 ling catheter drainage and two patients with hematuria, one of whom required overnight bladder irriga
193 , on further classification by time-averaged hematuria, only those patients with time-averaged protei
194 6 years, range of 18-86 years) evaluated for hematuria or a history of urothelial cancer, who had und
196 ing a similar protocol, no animals developed hematuria or glomerulonephritis, despite having identica
198 od urea nitrogen, creatinine, bleeding time, hematuria or proteinuria, and aspartate aminotransferase
203 ptoms: pain (P < .001), shivers, (P = .020), hematuria (P < .001), hematochezia (P < .001), and hemoe
205 e Lama5(neo) allele) results in proteinuria, hematuria, polycystic kidney disease (PKD), and death 3
206 teriorate within 3-6 days, with oliguria and hematuria progressing to anuria, and the kidneys were ex
207 ome is an inherited disease characterized by hematuria, progressive renal failure, hearing loss, and
210 of treatment-weighted hazard ratios (HRs) of hematuria, proteinuria, and kidney failure with replacem
212 uating renal inflammation, using microscopic hematuria, proteinuria, estimated glomerular filtration
213 2.0 microg/kg; n = 5) to renal failure with hematuria, proteinuria, thrombocytopenia, schistocytosis
215 ignificantly associated with higher rates of hematuria-related complications (including emergency dep
217 median follow-up of 7.3 years, the rates of hematuria-related complications were 123.95 events per 1
218 unexposed to thrombotic agents, the rates of hematuria-related complications were 191.61 events per 1
224 wn markers, including long-term follow-up of hematuria screening, recent studies in DNA methylation f
225 creatinine ratio (abnormal: >/=0.20 mg/mg); hematuria-spot urine dipstick (abnormal: 1+ or greater)
227 , increases C3 concentrations, and decreases hematuria, suggesting that the drug has immunomodulatory
228 s C), rigors, malaise, lethargy, flank pain, hematuria, suprapubic discomfort, dysuria, and urgent or
229 antly greater among patients with persistent hematuria than patients with minimal or negative hematur
231 nic thrombotic microangiopathy together with hematuria, thrombocytopenia, elevated creatinine, and ev
232 ultivariable analysis revealed time-averaged hematuria, time-averaged proteinuria, renal function at
234 nical manifestations range from asymptomatic hematuria to progressive chronic kidney disease (CKD), w
236 dominal/right upper quadrant gunshots and/or hematuria underwent mandatory CT with intravenous contra
237 the sensitivity or specificity of tests for hematuria, urinary cytology, or other urinary biomarkers
239 1 (Gd-IgA1), percentage of participants with hematuria, urine protein-creatinine ratio (UPCR), and eG
240 th a range of clinical presentations such as hematuria, voiding dysfunction, flank pain, abdominal pa
241 13 of 100 cycles and grade 3/4 hemorrhage or hematuria was 2%; the platelet transfusion rate was four
243 s showed that only microscopic nonglomerular hematuria was a significant risk factor for the developm
244 ilure and kidney relapse, whereas persistent hematuria was an independent predictor of kidney relapse
247 other relevant studies on the evaluation of hematuria was conducted, with particular emphasis on con
254 According to the magnitude of time-averaged hematuria, we classified patients as those with persiste
259 tumors can present with gross or microscopic hematuria, which is evaluated with cystoscopy and upper
260 ns included renal insufficiency, microscopic hematuria with active urine sediment, hypertension, and
262 ar-old female with TSC presenting as massive hematuria with underlying giant bilateral renal angiomyo
263 patient with HIV who presented with AKI and hematuria without concomitant systemic manifestations.